Treatment with IL‐33 dampens the inflammatory response linked to CDI by reducing pro‐inflammatory cytokines such as IL‐1β, IL‐6, and IL‐23, while boosting anti‐inflammatory cytokine production like IL‐4, IL‐5, and IL‐13. Here, IL1B is linked to clostridium difficile infection.